Graham Lumsden, Motif Bio’s chief executive, will give the presentation on Tuesday, 5 April.
BIO-Europe Spring is designed to provide top level partnering opportunities for smaller life science companies.
The conference annually attracts an international "who's who" from biotech, pharma, and finance for three days networking and meetings, Motif said.
The group recently dosed its first patient in one of two phase III clinical trials planned for iclaprim while it also appointed The Fulford Group to assist with the commercialisation of the drug.
Lumsden recently told Proactive Investors the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.